References of "Marre, Michel"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailWytyczne ESC dotyczace cukrzycy, stanu przedcukrzycowego i chorob ukladu sercowo-naczyniowego opracowane we wspolpracy z EASD.
Ryden, Lars; Grant, Peter J.; Anker, Stefan D. et al

in Kardiologia polska (2013), 71 Suppl 11

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailNovel Susceptibility Locus at 22q11 for Diabetic Nephropathy in Type 1 Diabetes
Wessman, Maija; Forsblom, Carol; Kaunisto, Mari A et al

in PLoS ONE (2011), 9(11), 24053

Background: Diabetic nephropathy (DN) affects about 30% of patients with type 1 diabetes (T1D) and contributes to serious morbidity and mortality. So far only the 3q21–q25 region has repeatedly been ... [more ▼]

Background: Diabetic nephropathy (DN) affects about 30% of patients with type 1 diabetes (T1D) and contributes to serious morbidity and mortality. So far only the 3q21–q25 region has repeatedly been indicated as a susceptibility region for DN. The aim of this study was to search for new DN susceptibility loci in Finnish, Danish and French T1D families. Methods and Results: We performed a genome-wide linkage study using 384 microsatellite markers. A total of 175 T1D families were studied, of which 94 originated from Finland, 46 from Denmark and 35 from France. The whole sample set consisted of 556 individuals including 42 sib-pairs concordant and 84 sib-pairs discordant for DN. Two-point and multi-point non-parametric linkage analyses were performed using the Analyze package and the MERLIN software. A novel DN locus on 22q11 was identified in the joint analysis of the Finnish, Danish and French families by genome-wide multipoint nonparametric linkage analysis using the Kong and Cox linear model (NPLpairs LOD score 3.58). Nominal or suggestive evidence of linkage to this locus was also detected when the three populations were analyzed separately. Suggestive evidence of linkage was found to six additional loci in the Finnish and French sample sets. Conclusions: This study identified a novel DN locus at chromosome 22q11 with significant evidence of linkage to DN. Our results suggest that this locus may be of importance in European populations. In addition, this study supports previously indicated DN loci on 3q21–q25 and 19q13. [less ▲]

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailEfficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes.
Puig, Juan Garcia; Marre, Michel; Kokot, Franciszek et al

in American Journal of Hypertension : Journal of the American Society of Hypertension (2007), 20(1), 90-7

BACKGROUND: Blood pressure control is the main influential variable in reducing microalbuminuria in patients with type 2 diabetes. In this subanalysis of the Natrilix SR versus Enalapril Study in ... [more ▼]

BACKGROUND: Blood pressure control is the main influential variable in reducing microalbuminuria in patients with type 2 diabetes. In this subanalysis of the Natrilix SR versus Enalapril Study in hypertensive Type 2 diabetics with micrOalbuminuRia (NESTOR) study, we have compared the effectiveness of indapamide sustained release (SR) and enalapril in reducing blood pressure and microalbuminuria in patients > or =65 years of age. METHODS: Of the 570 hypertensive patients with type 2 diabetes and persistent microalbuminuria in the NESTOR study, 187 (33%) individuals > or =65 years of age were included in this analysis. Of these, 95 patients received indapamide SR 1.5 mg and 92 patients received enalapril 10 mg, taken once daily in both cases. Adjunctive amlodipine and/or atenolol was added if required. RESULTS: The urinary albumin-to-creatinine ratio decreased by 46% in the indapamide SR group and 47% in the enalapril group. Noninferiority of indapamide SR over enalapril was demonstrated (P = .0236; 35% limit of noninferiority) with a ratio of 0.95 (95% CI: 0.68, 1.34). Mean arterial pressure decreased by 18 mm Hg and 15 mm Hg in the indapamide SR and the enalapril groups, respectively (P = .1136). The effects of both treatments seen in these elderly patients were similar to those observed in the main population, although the extent of the reduction in microalbuminuria was slightly higher. Both treatments were well tolerated, and no difference between groups was observed regarding glucose or lipid profiles. CONCLUSION: Indapamide SR is not less effective than enalapril in reducing microalbuminuria and blood pressure in patients aged >65 years of age with type 2 diabetes and hypertension. [less ▲]

Detailed reference viewed: 41 (0 ULg)
Full Text
Peer Reviewed
See detailEquivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR* study
Marre, Michel; Garcia Puig, Juan; Kokot, Franciszek et al

in Journal of Hypertension (2004), 22(8), 1613-1622

Objectives To test whether microalbuminuria in patients with type 2 diabetes and hypertension is primarily dependent on the severity of hypertension, and to compare the effectiveness of two anti ... [more ▼]

Objectives To test whether microalbuminuria in patients with type 2 diabetes and hypertension is primarily dependent on the severity of hypertension, and to compare the effectiveness of two anti hypertensive drugs with opposite effects on the renin-angiotensin system [the diuretic, indapamide sustained release (SR), and an angiotensin-converting enzyme inhibitor, enalapril] in reducing microalbuminuria. Design A multinational, multicentre, controlled, double-blind, double-dummy, randomized, two-parallel-groups study over 1 year. Methods After a 4-week placebo run-in period, 570 patients (ages 60.0 +/- 9.9 years, 64% men) with type 2 diabetes, essential hypertension [systolic blood pressure (SBP) 140-180 mmHg, and diastolic blood pressure (DBP) < 110 mmHg], and persistent microalbuminuria (20-200 mu g/min) were allocated randomly to groups to receive indapamide SR 1.5 mg (n = 284) or enalapril 10 mg (n = 286) once a day. Amlodipine, atenolol, or both were added, if necessary, to achieve the target blood pressure of 140/85 mmHg. Results There was a significant reduction in the urinary albumin: creatinine ratio. Mean reductions were 35% [95% confidence interval (Cl) 24 to 43] and 39% (95% Cl 30 to 47%) in the indapamide SR and enalapril groups, respectively. Equivalence was demonstrated between the two groups [1.08 (95% Cl 0.89 to 1.31%); P = 0.01]. The reductions in mean arterial pressure (MAP) were 16.6 +/- 9.0 mmHg for the indapamide SR group and 15.0 +/- 9.1 mmHg for the enalapril group (NS); the reduction in SBP was significantly greater (P = 0.0245) with indapamide SR. More than 50% of patients in each group required additional antihypertensive therapy, with no differences between groups. Both treatments were well tolerated. Conclusions lndapamide-SR-based therapy is equivalent to enalapril-based therapy in reducing microalbuminuria with effective blood pressure reduction in patients with hypertension and type 2 diabetes. [less ▲]

Detailed reference viewed: 37 (0 ULg)
Peer Reviewed
See detailRenal response to increasing doses of angiotensin converting enzyme inhibitor (ACEI) in type 1 diabetes mellitus according to ACE I/D polymorphism
Weekers, Laurent ULg; Bouhanick, Béatrice; Gallois, Yves et al

in Nephrology Dialysis Transplantation (2001), 16(6), 7

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailGénétique de la Néphropathie diabétique
Hadjadj, Samy; Weekers, Laurent ULg; Marre, Michel

in Sang Thrombose Vaisseaux [=STV] (2000), 12(3), 151-156

Detailed reference viewed: 18 (4 ULg)
Peer Reviewed
See detailGenetic polymorphism of transforming growth factor-β1 and microvascular complications in type 1 diabetes
Weekers, Laurent ULg; Hadjadj, Samy; Bouhanick, Béatrice et al

in Diabetologia (2000), 43(1), 137

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailLa variation de l’équilibre glycémique (mais pas du poids) est corrélée positivement à la modification du risque cardiovasculaire absolu chez le patient diabétique
Hadjadj, Samy; Guilloteau, Gérard; Weekers, Laurent ULg et al

in Archives des Maladies du Coeur et des Vaisseaux (2000), 93(8), 1033-1036

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailGenetic polymorphism of transforming growth factor-β1 and microvascular complications in type 1 diabetes
Weekers, Laurent ULg; Hadjadj, S.; Bouhanick, B. et al

Conference (2000)

Detailed reference viewed: 10 (0 ULg)
Peer Reviewed
See detailLa variation de l’équilibre glycémique (mais pas du poids) est correlée positivement à la modification du risque cardio-vasculaire absolu chez le sujet diabétique
Hadjadj, Samy; Guilloteau, Gérard; Weekers, Laurent ULg et al

in Archives des Maladies du Coeur et des Vaisseaux (1999), 92

Detailed reference viewed: 11 (0 ULg)